Beyond anti-VEGF: expanding the therapeutic horizon and biomarker landscape in retinopathy of prematurity
Emerging therapies targeting multiple pathogenic mechanisms, combined with novel biomarkers for risk stratification and treatment monitoring, show potential for more personalized and effective ROP management. Future research should focus on validating these biomarkers in diverse populations and optimizing combination therapy protocols to minimize treatment burden while maximizing visual outcomes and systemic safety.
Authors
- Jianli Lv (ORCID: https://orcid.org/0000-0001-8098-4692)
- Zheng Li (ORCID: https://orcid.org/0000-0002-8837-0318)
- Qian Chen (ORCID: https://orcid.org/0009-0003-8190-8482)
Institutions
- Qingdao University (CN)
- Shandong Provincial Hospital (CN)
- Shandong Maternal and Child Health Hospital (CN)
- Shandong First Medical University (CN)
- Qingdao Women and Children's Hospital (CN)
Publication Details
- Journal
- Frontiers in Pediatrics
- Published
- 2026-01-30
- DOI
- https://doi.org/10.3389/fped.2025.1713783
- Primary Topic
- Retinopathy of Prematurity Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Qingdao University
- Shandong First Medical University